Winslow Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Winslow Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-9	Closed	-$3K	–	97
2017 Q4	$3K	Hold	9	–	–	﹤0.01%	88
2017 Q3	$4K	Sell	9 -10	-53%	-$4.76K	﹤0.01%	78
2017 Q2	$9K	Sell	19 -561,907	-100%	-$246M	﹤0.01%	71
2017 Q1	$218M	Sell	561,926 -212,592	-27%	-$78.8M	1.04%	54
2016 Q4	$284M	Buy	774,518 +7,498	+1%	+$2.85M	1.31%	28
2016 Q3	$308M	Sell	767,020 -68,417	-8%	-$27.4M	1.28%	28
2016 Q2	$292M	Buy	+835,437	New	+$322M	1.19%	39
2016 Q1	–	Sell	-278,602	Closed	-$151M	–	151
2015 Q4	$151M	Sell	278,602 -18,449	-6%	-$10M	0.54%	61
2015 Q3	$138M	Buy	+297,051	New	+$160M	0.5%	62
2014 Q3	–	Sell	-7	Closed	-$2K	–	82
2014 Q2	$2K	Buy	+7	New	+$2.08K	﹤0.01%	72

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Winslow Capital Management's REGN Position: Q1 2018 in Review

Winslow Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2018, closing a stake of 9 shares — an estimated $3K sold.

Winslow Capital Management first reported a position in REGN in Q2 2014 and held it in 10 quarters. The position peaked at $308M in Q3 2016. 619 funds tracked by Wall St. Rank hold REGN as of Q1 2018.

Winslow Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Winslow Capital Management sold 9 Regeneron Pharmaceuticals shares in Q1 2018, an estimated $3K.
Winslow Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2014 and held it in 10 quarters.
Winslow Capital Management's Regeneron Pharmaceuticals position peaked at $308M in Q3 2016.
619 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2018.

Based on Winslow Capital Management's 13F filing for Q1 2018, filed 14 May 2018.